Appili Therapeutics Says FDA Approves LIKMEZ Metronidazole Oral Suspension
(RTTNews) - Biopharmaceutical company Appili Therapeutics, Inc. (APLI.TO, APLIF.PK) announced Monday that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC received approval from the U.S. Food and Drug Administration (FDA) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).
ATI-1501, Appili's liquid oral reformulation of the antibiotic metronidazole, has been licensed to Saptalis for commercialization in the U.S., and other selected territories. The FDA also approved LIKMEZ as the brand name for ATI-1501.
Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the U.S. every year to help treat parasitic and anaerobic bacterial infections.
The current tablet form of metronidazole is the only other approved oral form on the U.S. market.
Appili expects to receive milestone payments and royalties from Saptalis based on this FDA approval and Saptalis' commercialization plans.
Pound Rises On Upbeat U.K. GDP Data
Deere Stock Drops On Revised FY25 Outlook, Even As Q3 Beats Street
FTSE Down Marginally As Stocks Turn In Mixed Performance
Pound Rises Against Most Majors
CAC Rises For 3rd Straight Session
Sensex, Nifty End Little Changed As Traders Eye US-Russia Talks
Eurozone GDP Rises 0.1% As Estimated
